Herpes Simplex Virus News and Research

RSS

Anna Nele Meckler and Armelle Corpet to receive SNSF's 2015 Marie Heim-Vögtlin Prize

The biologist Armelle Corpet and paleo-climatologist Anna Nele Meckler will receive the 2015 Marie Heim-Vögtlin (MHV) Prize. This distinction rewards their remarkable scientific work supported by a MHV grant. The prize will be bestowed on 23 September 2015 at the Swiss National Science Foundation.

4 Jun 2015

Roche announces FDA 510(k) clearance for cobas HSV 1 and 2 Test

Roche announced today that the US Food and Drug Administration has provided 510(k) clearance for the cobas HSV 1 and 2 Test for the direct detection and differentiation of HSV-1 and HSV-2 DNA in anogenital specimens from symptomatic patients. With dual target detection and automation, the cobas HSV 1 and 2 Test provides laboratories with the capability to report up to 94 results in significantly less time than traditional methods and provides a simplified workflow for sample handling in the laboratory.

4 Jun 2015

Roche announces FDA clearance for cobas Cdiff Test to detect C. difficile in stool specimens

Roche announced today that the US Food and Drug Administration has provided 510(k) clearance for the cobas Cdiff Test to detect Clostridium difficile (C. difficile) in stool specimens.

26 May 2015

NanoViricides' anti-viral drug candidates show promise in lethal animal model of dermal herpes infection

NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, discusses the significance of the strong effectiveness demonstrated by its anti-viral drug candidates in a lethal animal model of dermal herpes infection.

27 Apr 2015

Trio of Andor EMCCD cameras chosen to unravel the inner structure of Herpes simplex virus

Although super-resolution light microscopy has broken new ground in our understanding of subcellular structures and the movement of individual molecules within cells, its use to investigate virus particles is in its infancy...

From Andor Technology Ltd. 14 Apr 2015

St. Luke’s Cancer Center offers new Phase II oncolytic viral therapy clinical trial for advanced melanoma

St. Luke’s Cancer Center is a leader in offering clinical trials for patients with melanoma, the most unusual type of skin cancer and also the most deadly. Physicians such as Sanjiv Agarwala, MD, Chief of Medical Oncology and Hematology for St. Luke’s University Health Network and an internationally recognized melanoma specialist, are committed to bringing the most promising studies to the Lehigh Valley.

8 Apr 2015

Rare genetic mutation explains why flu can kill in rare cases

Nobody likes getting the flu, but for some people, fluids and rest aren't enough. A small number of children who catch the influenza virus fall so ill they end up in the hospital — perhaps needing ventilators to breathe — even while their family and friends recover easily. New research by Rockefeller University scientists, published March 26 in Science, helps explain why: a rare genetic mutation.

30 Mar 2015

Personalized gene therapy to fight against cancer

The fight to treat cancer and eradicate tumors will likely benefit from a new set of treatments if early development phases continue to show promise, according to Kalorama Information. The healthcare market research publisher stated that gene therapies that are able to deliver genetic material to a specific cell population or tumor that will result in the destruction of the tumor.

25 Mar 2015

Common herpes drug Valacyclovir decreases HIV-1 levels

Case Western Reserve researchers are part of an international team that has discovered that a common herpes drug reduces HIV-1 levels — even when patients do not have herpes.

16 Mar 2015

Scientists design a promising vaccine for herpes viruses

Herpes simplex virus infections are an enormous global health problem and there is currently no viable vaccine.

9 Mar 2015

New type of vaccine holds promise for prevention of genital herpes

Scientists at Albert Einstein College of Medicine of Yeshiva University have designed a new type of vaccine that could be the first-ever for preventing genital herpes--one of the most common sexually transmitted diseases, affecting some 500 million people worldwide.

9 Mar 2015

Johns Hopkins researchers successfully deliver new nanoparticle gene therapy to treat glioma in rats

Despite improvements in the past few decades with surgery, chemotherapy and radiation therapy, a predictably curative treatment for glioma does not yet exist. New insights into specific gene mutations that arise in this often deadly form of brain cancer have pointed to the potential of gene therapy, but it's very difficult to effectively deliver toxic or missing genes to cancer cells in the brain.

5 Feb 2015

SLU investigators find promising candidates for new herpes virus treatments

Saint Louis University research findings published in the December issue of Antimicrobial Agents and Chemotherapy report a family of molecules known as nucleotidyltransferase superfamily (NTS) enzyme inhibitors are promising candidates for new herpes virus treatments.

19 Dec 2014

Study reports effective treatment approach to inhibit herpes virus infection

A multi-institutional study reports an effective treatment approach to inhibit and keep latent viruses like herpes simplex from reactivating and causing disease. The work, whose lead author is the late James Hill, PhD, LSU Health New Orleans Professor and Director of Pharmacology and Infectious Disease at the LSU Eye Center, is published in the December 3, 2014, issue of Science Translational Medicine.

4 Dec 2014

Chemotherapy drug combined with cancer-killing virus may treat recurrent ovarian cancer

In six out of 10 cases, ovarian cancer is diagnosed when the disease is advanced and five-year survival is only 27 percent.

14 Nov 2014

Profectus BioSciences gets funding to develop VesiculoVax Zaire-Ebola virus vaccine

Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the treatment and prevention of infectious diseases, announced today that the Department of Defense through the Medical Countermeasure Systems-Joint Vaccine Acquisition Program, a subordinate command of the Joint Program Executive Office for Chemical and Biological Defense, Edgewood, MD, has contracted the manufacture and IND-enabling preclinical testing of the Profectus trivalent Ebola/Marburg vaccine.

31 Oct 2014

Infection with herpes simplex virus increases Alzheimer's risk

Infection with herpes simplex virus increases the risk of Alzheimer's disease. Researchers at Umeå University, Sweden, claim this in two studies in the journal Alzheimer's & Dementia.

20 Oct 2014

NanoBio to highlight prophylactic NE HSV-2 vaccine candidate at The Keystone Symposia Conference

NanoBio Corporation today announced that the company will present data at The Keystone Symposia Conference, The Modes of Action of Vaccine Adjuvants, in Seattle on October 12, 2014.

9 Oct 2014

Mymetics' innovative HIV vaccine candidate to enter new preclinical trial

Mymetics Corporation, a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate will enter a new preclinical trial to confirm excellent results obtained in a previous trial.

30 Sep 2014

Study: 15,000 pregnant women show decreased amount of prevalence of HSV type 2

In a study that included approximately 15,000 pregnant women, seroprevalence of herpes simplex virus (HSV) type 2 decreased substantially between 1989 and 2010 while there was no overall decrease for HSV type 1, but a slight increase among black women, according to a study in the August 20 issue of JAMA.

20 Aug 2014